S100A4 amplifies TGF-β-induced epithelial–mesenchymal transition in a pleural mesothelial cell line

Qian Ning, Feiyan Li, Lei Wang, Hong Li, Yan Yao, Tinghua Hu, Zhongmin Sun

ABSTRACT
Pleural fibrosis can dramatically lower the quality of life. Numerous studies have reported that epithelial–mesenchymal transition (EMT) regulated by transforming growth factor-β (TGF-β) is involved in fibrosis. However, the molecular mechanism is inadequately understood. Fibroblast-specific protein-1 (S100A4) is a target of TGF-β signaling. In our previous study, we have reported that S100A4 is highly expressed in pleural fibrosis. Thus, we suggest that S100A4 took part in the TGF-β-induced EMT in pleural fibrosis. In this study, we determined the expression of S100A4 and EMT-related markers in Met-5A cells (pleural mesothelial cells) treated with TGF-β or TGF-β inhibitor by real-time PCR and western blot. In order to explore the role of S100A4, we used siRNA to knock down the expression of S100A4 in cell model. We found that the expression of epithelial cell marker was decreased and the mesenchymal cell marker increased with S100A4 upregulation after treatment with TGF-β. Moreover, the changes of EMT-related event were restricted when the expression of S100A4 was knocked down. Conversely, S100A4 can partially rescue the EMT-related expression changes induced by TGF-β inhibitor. These findings suggest that S100A4 expression is induced by the TGF-β pathway, and silencing S100A4 expression can inhibit the process of TGF-β-induced EMT.

INTRODUCTION
Pleural fibrosis can cause serious restrictive ventilatory functional disturbance and dramatically lower the quality of life. However, the pathogenesis of pleural fibrosis is inadequately understood. Recently, certain studies have demonstrated that transforming growth factor-β (TGF-β) signaling pathway is involved in fibrosis of some organs, such as liver, kidney and lung.1–3 TGF-β regulates cell apoptosis, cell proliferation, cell migration, cell differentiation and extracellular matrix production, and so on. Also, TGF-β can induce pleural fibrosis through the generation of extracellular matrix and reduce its degradation.4 Reports have shown that in the process of fibrosis, epithelial cells can be transformed into fibroblasts, a process called epithelial–mesenchymal transition (EMT).5 TGF-β is a powerful mediator of EMT.

EMT is an essential developmental process. It participates in mature tissue healing, remodeling and recovery from injury, through which the epithelial cells lose their polarity and acquire mesenchymal phenotypes, including fibroblast-like morphology and increased potential for motility. EMT also takes part in many pathologic processes, such as inflammation, rheumatoid arthritis, tumor metastasis and chronic organ fibrosis, including lung, liver and kidney.

TGF-β can induce the expression of fibroblast-specific protein-1 (S100A4) in renal tubular epithelial cells, while the expression of mesenchymal cell markers is upregulated and epithelial cell markers downregulated.6 S100A4, a kind of Ca2+–binding proteins with the double helix structure of EF hand, is thought to be specifically expressed in fibroblast in the past years. However, the latest researches report S100A4 is widely expressed in normal cells, such as monocytes, macrophage, T cells, neutrophil and endothelial cells.7 S100A4 was related to various diseases, including tumor, rheumatoid arthritis, lung disease, vascular disorder, nerve injury, myocardial hypertrophy and regeneration of repaired cornea. It affects
the function of numerous intracellular molecular through protein–protein interaction. Numerous studies have shown that S100A4 plays an important role in tumor metastasis. S100A4 maintains cancer-initiating cells in head and neck cancers.8 Also previous research reported S100A4 was closely related to renal and liver fibrosis through EMT.9 But the role of S100A4 in TGF-β-mediated pleural fibrosis remains unknown. Since S100A4 was highly expressed in fibrotic pleural tissue,10 we sought to examine the association between TGF-β and S100A4 in phenotype transition of pleural mesothelial cells (PMCs) and pleural fibrosis. In the present study, we demonstrated the expression changes of S100A4, and EMT-related markers in Met-5A cells treated with TGF-β and its inhibitor. Also we observed the effect of S100A4 on EMT-related marker expression. Our data suggested that the S100A4 expression is induced by the TGF-β pathway, and silencing the expression of S100A4 can inhibit the process of TGF-β-induced EMT. This finding might pave the way for new and effective treatment for pleural fibrosis.

**MATERIALS AND METHODS**

**Cell line, culture conditions and treatment**

The human PMC line, Met-5A, was purchased from the American Type Culture Collection (ATCC). The cells were cultured in Medium 199 (Hyclone) supplemented with 10% fetal calf serum (Gibco), 3.3 nm epidermal growth factor (Abcam), 400 nM hydrocortisone (Sigma), 870 nM zinc-free bovine insulin (Novo Nordisk), 20 mM HEPES (Gibco), 3.87 µg/L selenious acid (H₂SeO₃, Sigma) and trace elements B (Biodee, Beijing, China) liquid used at 1:100 dilution in a 5% CO₂ and 95% air incubator at 37°C. Cells were cultured in the absence of serum overnight prior to the treatment with LY2157299 (30 ng/mL, Selleck Chemicals) for the indicated periods.

**Cell proliferation and viability**

Met-5A cells were plated at a density of 3×10⁴ cells/mL in 96-well plates (100 µL medium per well). Twenty-four hours after seeding, the cells were treated with TGF-β and six replicates were included for each concentration (1.0 ng/mL, 5.0 ng/mL, 10.0 ng/mL, 20.0 ng/mL). Cell proliferation and viability were measured using the Cell Counting Kit-8 (CCK-8) (Dojindo, Kumamoto, Japan) and a microplate reader (SpectraMax Plus 384, Molecular Devices, Sunnyvale, California, USA) at a wavelength of 450 nm.

**Transfection**

SiRNA targeting S100A4 was chemically synthesized by Hangzhou Hibio Technologies. The target sequence for S100A4-siRNA was 5’-UCACACAAGUCAGACGCUAAA-3’. Twenty-four hours before transfection, cells were seeded onto 6-well culture plates. When cells grew to 80%–90% confluence, transfection was performed using Lipofectamine 2000 Reagent (Life Technologies) according to manufacturer’s instructions. The expressions of TGF-β, S100A4, α-smooth muscle aorta ( SMA) and cytokeratin were confirmed by real-time RCR and western blot after 48 hours.

**Real-time PCR**

Total RNA of the cells was extracted with Trizol reagent (Invitrogen) according to the manufacturer’s instructions. Primers for the target gene were designed by Hangzhou Hibio Technologies (table 1). CDNA was synthesized using the RevertAid First Strand cDNA Synthesis Kit (Fermentas). All PCR reactions were carried out using a SuperReal PreMix Plus (with SYBR Green I) (Tiangen) according to the manufacturer’s instructions. Amplification was performed using a CFX Connect Real-Time PCR System. The expression levels of the target mRNAs were directly normalized to GAPDH.

**Western blotting analysis**

The Met-5A cells were lysed in phenylmethylsulfonyl fluoride at 4°C for 30 min, and then centrifuged at 11 000 rpm for 5 min at 4°C. The supernatant was collected for total cellular protein, and its concentration was determined using the Bradford assay (Sigma Chemicals, Bangalore, India). Equivalent amounts of total cellular protein (30 µg) were fractionated on a reducing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (8%–12%), followed by blotting on a polyvinylidene difluoride membrane. Membranes were blocked in 5% non-fat dry milk for 2 hours, and then incubated with the following antibodies overnight at 4°C: anti-TGF-β (Millipore), anti-S100A4 (Santa Cruz Biotechnology), anti-α-SMA (Santa Cruz Biotechnology) and anticytokeratin (CST). An horse-radish peroxidase (HRP)-conjugated secondary antibody (Santa Cruz Biotechnology) was applied, and a chemiluminescent substrate system (Amersham Biosciences) was used to detect the signals. Images were documented by scanner.

**Table 1** Sequences of primers for TGF-β, S100A4, α-SMA, keratin 7 and GAPDH

| Sequence         | Expected lengths |
|------------------|------------------|
| **TGF-β**        |                  |
| Forward: 5’-AACATGATCTGCGCTCTGCAAGTGCAGC- 3’ | 200 bp |
| Reverse: 5’-AGGAGCCGACACAGTGATA-AGGAA- 3’ | |
| **S100A4**       |                  |
| Forward: 5’-AGGGACACCGAGGCTGACTTC3’ | 105 bp |
| Reverse: 5’-CTTCTGTGGCTGCTTATCGG-3’ | |
| **α-SMA**        |                  |
| Forward: 5’-AGGGTGTTGCTATTCTCTTGTA3’ | 153 bp |
| Reverse: 5’-GCCCATCAGGGCCATCTGGA-A-3’ | |
| **Cytokeratin**  |                  |
| Forward: 5’-CTTGGCGACAGCGACGCTTCA3’ | 239 bp |
| Reverse: 5’-TCCAGAAACCGCACCCGCTGTC3’ | |
| **GAPDH**        |                  |
| Forward: 5’-AGAGGGCTCTGGGCTATTTC-3’ | 258 bp |
| Reverse: 5’-AGGGGCCATCCACAGTCTC-3’ | |

**α-SMA**, smooth muscle aorta; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TGF-β, transforming growth factor-β.
and analyzed by Quantity One software. β-actin expression was used as a loading control.

Immunohistochemical staining

Cells were seeded on poly-L-lysine-coated glass coverslips in 6-well plates and received different treatments. After being fixed with 4% paraformaldehyde for 15 min, cells were permeabilized in 0.5% Triton X-100 for 20 min, and subsequently incubated with 0.3% hydrogen peroxidase for 10 min in order to block endogenous peroxidase activity. Slides were incubated with normal goat serum for 1 hour to block unspecific labeling. Subsequently, cells were incubated with the following antibodies overnight at 4°C: anticytokeratin (CST) and α-SMA (Abcam). Slides were then washed in phosphate buffer saline (PBS) followed by incubation with secondary antibody (Wuhan Boster Biological Engineering) for 1 hour at 37°C, followed by incubation with streptavidin-peroxidase (Dako) for 15 min at 37°C. 3,3′-diaminobenzidine (DAB, Dako) was applied as the chromogenic agent. Then slides were counterstained with hematoxylin, dehydrated in graded ethanol and coverslipped. Cells were observed under a fluorescent microscope.

Statistical analysis

Statistical analysis of data was performed using SPSS V.22.0 for Windows software. All data from experiments are presented as the mean±SE. One-way analysis of variance or two-tailed Student’s t-tests were used for comparisons between groups. p<0.05 was considered to be statistically significant.

RESULTS

Effect of TGF-β on the proliferation of Met-5A

First, we detected the effect of TGF-β on the proliferation of Met-5A cells using CCK-8 method. TGF-β induced a clear dose-dependent increase in the viability of Met-5A cells after 48-hour exposure. Significant increase of cell viability was observed when TGF-β concentration was higher than 1.0 ng/mL, and the cell viability reached plateau phase at the concentration of 10.0 ng/mL (figure 1).

Effect of TGF-β on the expression of S100A4

It is obvious that TGF-β participates in pleural fibrosis, but the mechanism was not known by now. In our previous study, we have reported that S100A4 is highly expressed in pleural fibrosis. In order to check whether S100A4 was involved in the TGF-β-mediated pleural fibrosis, we first examined the mRNA and protein expression of S100A4 in Met-5A cells treated with different expression levels of TGF-β. Our results showed that TGF-β treatment led to an increase in the expression of S100A4, and the S100A4 level was decreased when Met-5A cells were treated with LY2157299, an inhibitor of TGF-β receptor. However, the expression of S100A4 in Met-5A cells treated with

Figure 1 Effect of TGF-β on the proliferation of Met-5A cells. Met-5A cells were treated with 1.0 ng/mL, 5.0 ng/mL, 10.0 ng/mL and 20.0 ng/mL TGF-β, respectively. Cell proliferation was measured by CCK-8. TGF-β induced a clear dose-dependent increase in the viability of Met-5A cells after 48-hour exposure. Data are presented as average±SD for three independent experiments. **p<0.01 indicates significant difference between exposed and untreated Met-5A cells. CCK-8, Cell Counting Kit; TGF-β, transforming growth factor-β.

Figure 2 Effect of TGF-β on the expression of S100A4 in Met-5A cells. Met-5A cells were treated with TGF-β and/or LY2157299. S100A4 mRNA (A, real-time PCR) and protein (B, western blot) levels were upregulated after 48 hours of TGF-β treatment, while downregulated 48 hours after LY2157299 treatment. TGF-β can rescue the expression changes induced by LY2157299. The bar graph shows the relative mRNA or protein expression levels among groups. GAPDH and β-actin were used as an endogenous control for normalization. Data are presented as average±SD for three independent experiments. *p<0.05 indicates significant difference between treated and control groups. TGF-β, transforming growth factor-β.
LY2157299 was significantly increased after treatment with TGF-β for 48 hours to activate TGF-β, in both the mRNA and protein levels (figure 2).

**Effect of S100A4 in regulating EMT in Met-5A cells**
As previously described, EMT plays an important role in chronic organ fibrosis. To investigate whether S100A4 took part in EMT in Met-5A cells, we examined the expression of α-SMA (mesenchymal cell marker) and cytokeratin (epithelial cell marker) using real-time PCR, western blot and immunohistochemical analysis. As expected, we found that S100A4 treatment resulted in an increase in the expression of mesenchymal cell marker and a decrease in the expression of epithelial cell marker in Met-5A cells. Conversely, downregulation of S100A4 reversed these expression changes (figure 3).

**Effect of S100A4 on the expression of EMT-related markers in Met-5A cells treated with LY2157299**
It has been widely reported that TGF-β was a powerful EMT regulator. Consistent with previous reports, TGF-β induced an increase in the expression of α-SMA and a decrease in cytokeratin in Met-5A cells, in both the mRNA and protein levels. As we reported above, S100A4 was a molecular marker that can initiate EMT. In order to explore the role of S100A4 in TGF-β-induced EMT, we analyzed the expression of EMT-related markers when Met-5A cells were treated with LY2157299, and found the expression of cytokeratin was enhanced and α-SMA decreased, at both the mRNA and protein levels. And as expected, S100A4 could partially reverse the expression changes. Meanwhile, when the expression of S100A4 was downregulated, the expression of α-SMA was partially decreased and cytokeratin partially increased in Met-5A cells treated with TGF-β, compared with cells exposed to TGF-β only. In other words, downregulation of S100A4 could partially prevent the EMT initiated by TGF-β. Thus, these results indicated that S100A4 played a pivotal role in TGF-β-induced EMT in a PMC line (figure 4).

**DISCUSSION**
Any disease-infected pleura with inadequacy treatment can cause pleural fibrosis, which manifests as pleural thickening and adhesion. Pleural fibrosis can cause different levels of respiratory dysfunction. However, there is no effective method to cure pleural fibrosis at present. Understanding the molecular mechanisms underlying the progression of pleural fibrosis may provide
ways for the development of antipleural fibrosis therapies. In this study, we investigated the role of S100A4 in TGF-β-induced fibrosis.

PMCs play a significant role in the pathogenesis of pleural fibrosis, and their response to inflammation is an important element in this condition. Huggins and Sahn\(^{11}\) reported that the reaction of mesothelial cells and its basement membrane to pleural injury and inflammation, along with their ability to self-repair, determines the prognosis, in other words whether there is normal healing or pleural fibrosis. Nathalie et al\(^{12}\) transferred TGF-β into the PMCs of rats, which induced the occurrence of pleural fibrosis and caused serious lung capacity limits.\(^{12}\) Also we chose Met-5A cell line as our cell model.

Existing reports have demonstrated that the first step of fibrosis is tissue damage caused by a chronic inflammation. Then activated myofibroblasts migrated to the inflammatory sites to induce wound healing. Finally, fibrosis forms due to excessive deposition of extracellular matrix (ECM).\(^{5 13}\) In this process, epithelial cells can be transformed into myofibroblasts, called EMT. TGF-β is the key factor in organ fibrosis and tumor metastasis, and also involved in EMT. Gauldie J et al\(^{14}\) reported upregulation of TGF-β in lung tissue can induce severe and progressive fibrosis in rodent

![Figure 4](image)

**Figure 4** Effect of S100A4 on the expression of EMT-related markers in Met-5A cells treated with LY2157299. Met-5A cells were transfected with S100A4 siRNA to inhibit TGF-β-induced EMT, or treated with S100A4 to activate the TGF-β–EMT pathway. The mRNA and protein expression of EMT-related markers were determined by real-time PCR (A) and western blot (B), respectively. GAPDH and β-actin were used as an endogenous control for normalization. The bar graphs show the relative expression of mRNA or proteins among each treatment groups. Data are presented as average±SD for three independent experiments. *p<0.05 indicates significant difference between treated and control groups. EMT, epithelial–mesenchymal transition; TGF-β, transforming growth factor-β.
lung. The expression level of TGF-β in pleural effusion is positively correlated with pleural thickening in experimental empyema, and intrapleural injection of TGF-β antibody will inhibit pleural fibrosis. TGF-β regulates cell proliferation in numerous cell lines. Consistent with the previous report, our data showed that TGF-β promotes the proliferation of PMCs.

S100A4 played important role in organ fibrosis. In our previous study, we have reported that S100A4 is highly expressed in pleural tuberculosis. Xie R et al.17 found S100A4 mediated endometrial cancer invasion and was a target of TGF-β signaling. Matsuura et al.18 reported functional interaction between Smad3 and S100A4 became important regulator for TGF-β-mediated cancer cell invasion. However, there was no evidence showing the relationship between TGF-β and S100A4 in pleural fibrosis. In the present study, we found that TGF-β regulates the expression of S100A4 in Met-5A cells. This is direct evidence supporting the theory that S100A4 is a target of TGF-β signaling in PMCs.

Kim et al.19 found PMCs in pleural tuberculosis participated in pleural fibrosis through EMT. In the present study, we found S100A4 treatment led to an increase in the expression of mesenchymal cell marker and a decrease in the expression of epithelial cell marker in Met-5A cells. This is consistent with previous studies showing that S100A4 participates in the process of EMT. In order to check whether S100A4 was involved in the TGF-β-induced EMT, we examined the S100A4 expression in Met-5A cells when treated with TGF-β for 48 hours. The mRNA and protein expressions of S100A4 were increased, and also TGF-β treatment led to an increase in the expression of mesenchymal cell marker and a decrease in the expression of epithelial cell marker in Met-5A cells. Interestingly, down-regulation of S100A4 partially inhibited the TGF-β-mediated expression changes. These data told us that S100A4 might be a key factor in TGF-β-induced EMT.

Contributors QN, FL, LW, HL, YY and TH carried out the experiments, ZS designed the study, and QN and ZS prepared the manuscript. All authors read and approved the final manuscript.

Funding This study was supported by the National Natural Science Foundation of China (81170073).

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ © American Federation for Medical Research (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1 Kim YH, Kim KW, Lee KE, et al. Transforming growth factor-beta 1 in humidifier disinfectant-associated children’s interstitial lung disease. Pediatr Pulmonol 2016;51:173–82.
2 Roy S, Benz F, Vargas Cardenas D, et al. miR-30c and miR-193 are a part of the TGF-β-dependent regulatory network controlling extracellular matrix genes in liver fibrosis. J Dig Dis 2015;16:513–24.
3 Thakur S, Viswanathapalli S, Kopp JB, et al. Activation of AMP-activated protein kinase prevents TGF-β1-induced epithelial-mesenchymal transition and myofibroblast activation. Am J Pathol 2015;185:2168–80.
4 Mutsaers SE, Kalomenidis I, Wilson NA, et al. Growth factors in pleural fibrosis. Can Opin Pulm Med 2006;12:251–8.
5 Schair M, Huber N, Lang S, et al. Hallmarks of epithelial to mesenchymal transition are detectable in Cohlin’s disease associated intestinal fibrosis. Clin Transl Med 2015;4:1.
6 Vongveiwatana A, Tasanarong A, Rayner DC, et al. Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. Am J Transplant 2005;5:1367–74.
7 Boye K, Maelandsmo GM, S100A4 and metastasis: a small actor playing many roles. Am J Pathol 2010;176:528–35.
8 Lo JF, Yu CC, Chiou SH, et al. The epithelial-mesenchymal transition mediator S100A4 maintains cancer-initiating cells in head and neck cancers. Cancer Res 2011;71:1912–23.
9 Schneider M, Hansen JL, Sheikh SP. S100A4: a common mediator of epithelial-mesenchymal transition. fibrosis and regeneration in diseases? J Mol Med 2008;86:507–22.
10 Sun ZM, Li FY, Wang L, et al. Expression of fibroblast specific protein-1 in pleural tuberculosis and its clinical biological significance. World J Surg Oncol 2011;9:153.
11 Huggins JT, Sahn SA. Causes and management of pleural fibrosis. Respiriology 2004;9:441–7.
12 Decollegne N, Kolb M, Margetts PJ, et al. TGF-beta1 induces progressive pleural scarring and subpleural fibrosis. J Immunol 2007;179:6043–51.
13 Rieder F, Brenmoehl J, Leeb S, et al. Wound healing and fibrosis in intestinal disease. Gut 2007;56:130–9.
14 Gauldie J, Bonntraud P, Sime P, et al. TGF-beta, Smad3 and the process of progressive fibrosis. Biochem Soc Trans 2007;35(Pt 4):661–4.
15 Sasse SA, Jadus MR, Kubes GD. Pleural fluid transforming growth factor-beta1 correlates with pleural fibrosis in experimental empyema. Am J Respir Crit Care Med 2003;168:700–5.
16 Kunz CR, Jadus MR, Kubes GD, et al. Intrapleural injection of transforming growth factor-beta antibody inhibits pleural fibrosis in empyema. Chest 2004;126:1636–44.
17 Xie R, Schlumbrecht MP, Shipley GL, et al. S100A4 mediates endometrial cancer invasion and is a target of TGF-beta1 signaling. Lab Invest 2009;89:937–47.
18 Matsuura I, Lai CY, Chiang KN. Functional interaction between Smad3 and S100A4 (metastatin-1) for TGF-beta-mediated cancer cell invasiveness. Biochem J 2010;426:327–35.
19 Kim C, Kim DG, Park SH, et al. Epithelial to mesenchymal transition of mesothelial cells in tuberculous pleurisy. Yonsei Med J 2011;52:51–8.